Helping people who smoke to stop is one of the biggest prizes in US public health because smoking is still the country’s leading cause of preventable death. Advice from the medical profession potentially has a central role in helping to tackle the problem, so it is significant that new recommendations have recently been issued in the US. They advise US clinicians to include e-cigarettes as an option for patients who want to quit smoking and – equally importantly – to correct misperceptions related to the harm and safety of these products.
Tobacco harm reduction (THR), moving people who smoke to less harmful sources of nicotine, is often dismissed by critics as a tobacco-industry ploy. But the latest advice comes from a working group of the Society for Research on Nicotine and Tobacco (SRNT) – the main scientific society in the field – which published its piece in the prestigious Journal of the American Medical Association (JAMA), accompanied by an editorial from Dr Jamie Hartmann-Boyce.
The evidence has strengthened
The last significant US guidance, the American College of Cardiology’s 2018 consensus pathway and the US Preventive Services Task Force’s 2021 review, was written when the evidence base for e-cigarettes was weak, and left clinicians without a current, evidence-based way to discuss e-cigarettes. That has changed markedly: e-cigarettes, the working group writes, “are less harmful than cigarettes and have been shown to be more effective for smoking cessation than … approved nicotine replacement therapies.” The Cochrane living review now finds with high certainty that they outperform NRT; a second review puts them on a par with varenicline, the most effective approved medicine; and a 2026 overview found that all 21 comparisons with other quitting methods favored e-cigarettes, with no trial finding serious harm from using them to quit.
The central recommendation is thus that for adults who smoke, e-cigarettes should be offered as one of the quitting options, alongside the approved medicines: nicotine-replacement therapies (NRTs, such as patches and gum), varenicline and bupropion. Patients should not have to try and fail on a medication approved by the Food and Drug Administration (FDA) before e-cigarettes are discussed as an option; the point is to get them off cigarettes.
Correcting misperceptions
The article also exhorts doctors to correct misperceptions on e-cigarette safety. Many clinicians, and much of the public, now think e-cigarettes are as harmful as cigarettes or worse, a belief which has hardened even as the evidence has moved the other way. Some of that is down to confusion about nicotine, and a belief that it causes disease which is in fact caused by combustion; some is an unintended consequence of anti-youth-vaping campaigns that have, the authors say, confused adults who smoke and for whom e-cigarettes are the less harmful choice; and some is the shadow of the 2019 lung-injury outbreak, caused by illicit cannabis vapes cut with vitamin E acetate, but which got blamed on nicotine e-cigarettes at the time.
A debate about values, not only evidence
The accompanying editorial puts the article’s findings in a broader perspective, pointing out that clear evidence hasn’t so far settled controversies in this field because the disagreement is often about values rather than data, “… and that is much harder to untangle.” Harm reduction is broadly accepted elsewhere, including for people who use illicit drugs, but tobacco harm reduction has remained contentious.
One reason for that is that many in public health remain wary of the industry’s involvement in THR. Another is the concern that a positive press for e-cigarettes might encourage young people to take up vaping. But as Dr Hartmann-Boyce points out, industry involvement and worries about youth do not change the evidence on whether e-cigarettes help people quit. Is the goal eliminating nicotine addiction itself, or the disease burden that smoking causes? If it’s the latter, helping someone who cannot – or doesn’t want to – give up nicotine move to a far less harmful source is the kind of trade-off public health makes in other fields. And any qualms about nicotine itself ought also to apply to NRTs, available on prescription and, for the main forms, over the counter, and which the World Health Organization calls essential medicines.
US regulation isn’t serving consumers well
A further recommendation that the authors of the JAMA paper make is that patients should be advised to use e-cigarettes authorized by the FDA, on the basis that the agency will have reviewed their safety and found that placing them on the market is appropriate for the protection of public health. It’s true that FDA authorization ought to give a degree of confidence on product safety and effectiveness, but the problem is that – six years into the current regulatory regime – the FDA has authorized only 48 e-cigarette products for sale.
Until May 2026 the only flavors available in authorized products were tobacco and menthol; the FDA has now authorized two others, out of 45 products in total, although it is very well documented that adult vapers typically prefer a much wider range of offerings
Another just-published paper estimates that nearly 70% of e-cigarette products sold in the US grocery and convenience channels were unauthorized as of December 2025.
Conclusion
Even if regulation has not yet caught up, it’s very encouraging to us that US guidance on e-cigarettes is moving. The medical profession can play a very important role in increasing the acceptability of these and other products in tobacco harm reduction strategies, and in correcting public misperceptions. And the US remains enormously influential in helping to shape global perceptions; it would be very helpful to have another example alongside the likes of the UK and New Zealand of a country whose health establishment recognizes that e-cigarettes have a legitimate role to play in smoking cessation.

